



Synthesis, structures, antiproliferative activity of a series of ruthenium(II) arene derivatives of thiosemicarbazones ligands



Wei Su^a, Zhaofeng Tang^a, Qi Xiao^a, Peiyuan Li^{b,*}, Quanquan Qian^a, Xiaolin Lei^a, Shan Huang^a, Binghua Peng^a, Jianguo Cui^a, Chusheng Huang^a

^a Department of Chemistry, Guangxi Teachers Education University, Nanning 530001, China

^b College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530001, China

ARTICLE INFO

Article history:

Received 31 October 2014

Received in revised form

23 December 2014

Accepted 30 December 2014

Available online 11 February 2015

Keywords:

Ruthenium

Cytotoxicity

Arene

Thiosemicarbazone

ABSTRACT

A series of [(*p*-cymene)Ru(TSC)Cl]Cl compounds (**[1]**Cl, **[2]**Cl and **[3]**Cl) and their corresponding [(*p*-cymene)Ru(TSC)Cl][(p-cymene)RuCl₃] derivatives (**[1]**[(p-cymene)RuCl₃], **[2]**[(p-cymene)RuCl₃] and **[3]**[(p-cymene)RuCl₃]) have been synthesized and characterized by ¹H NMR, elemental analysis and HR-ESI-mass spectrometry. The molecular structures of **[2]**Cl, **[3]**Cl, **[1]**[(p-cymene)RuCl₃], **[2]**[(p-cymene)RuCl₃] and **[3]**[(p-cymene)RuCl₃] have been characterized by single-crystal X-ray diffraction analysis. The complexes have been further evaluated for their *in vitro* antiproliferative activities against the SGC-7901 human gastric cancer, BEL-7404 human liver cancer and HEK-293T noncancerous cell lines. Furthermore, the interactions of the complexes **[1]**Cl and **[1]**[(p-cymene)RuCl₃] with HSA have been followed by fluorescence spectrometry studies.

© 2015 Elsevier B.V. All rights reserved.

Introduction

The synthesis of half-sandwich ruthenium complexes containing η⁶-arene ligands has attracted increasing attention [1] for their potential applications as catalysts in synthetic organic chemistry [2] as well as metallopharmaceuticals in cancer therapy [3]. The hydrophobicity of arene ligand is deemed to facilitate the diffusion of the complexes through the lipophilic cell membrane when these complexes are employed as anticancer drug [4]. Meanwhile, the three remaining Ru coordination sites can be filled with various ligands, which offer possibilities to modulate biological and pharmacological properties by selecting proper ligand [5]. For instance, Ru arene complexes containing ethylenediamine (en) ligand have showed cytotoxicity toward cancer cells for their binding ability to DNA [3a], [6]. In addition, related complexes with 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]-decane (PTA) as the ligand, e.g. [(p-cymene)Ru(PTA)Cl₂] (RAPTA-C), have exhibited activity against metastases [3b], [7]. Besides en and PTA ligand, some other systems have been investigated in ruthenium-based complexes, including moieties incorporating N,N- [8], N,O- [9], O,O- [10], and O,S- [11]

chelating ligands and several monodentate biologically active ligands [12]. It is shown that the nature of the ligands, which can adjust the hydrophobicity of the compounds to penetrate the cell [13] or afford stability of the complexes in aqueous solution [11a], influences the *in vitro* anticancer activity significantly.

Thiosemicarbazones (TSCs), considered as one kind of the most important scaffolds, have been found to be incorporated in many biologically active compounds [14]. TSCs are capable of chelating with a broad range of metal ions to form stable organometallics, which have exhibited such pharmacological properties as antibacterial, antifungal, and antitumor activities and so on [15]. Particularly, the Ru-arene complexes with TSCs ligands have emerged as an approach to develop promising lead TSC-based therapeutic agents [16]. More recently, we have demonstrated the antiproliferative activity of TSCs and the corresponding Ru-arene (arene = η⁶-*p*-cymene) complexes [17], and the results have shown that the structures of the compounds have great effects on their antiproliferative activity.

Our motivation for improving the antiproliferative activity of the Ru-arene compounds is based on the adjustment of the structures of the compounds. Here, we report the controlled synthesis of a series of Ru-arene compounds, employing N⁴-phenyl-TSC as the ligands. Moreover, the relationships between the structures and antiproliferative activities are investigated. Specially, information are provided on the anticancer activity of the compounds [(arene)

* Corresponding author. No. 179, Mingxiudong Road, Nanning, China. Tel.: +86 07712975635.

E-mail address: lipearpear@163.com (P. Li).

$\text{Ru}(\text{TSC})\text{Cl}]^+[(\text{arene})\text{RuCl}_3]^-$ systems that possess an unusual organometallic counterion.

Experimental section

Materials

Ruthenium(III) chloride hydrate, TSC and other reagents were purchased from J&K chemical Co (China). All reagents and solvents were of high purity and used without further purification. The starting materials $[(p\text{-cymene})\text{RuCl}_2]_2$ were prepared according to literature methods [17]. All of the TSC ligands ($L' = L^1, L^2$ and L^3) were prepared by previously reported procedures [17].

Synthesis

$[(p\text{-cymene})\text{Ru}(L^1)\text{Cl}]\text{Cl}$ ([1]Cl). Compound [1]Cl was reported previously by us [17].

$[(p\text{-cymene})\text{Ru}(L^2)\text{Cl}]\text{Cl}$ ([2]Cl). Compound [2]Cl was synthesized as for [1]Cl. $[(p\text{-cymene})\text{RuCl}(\mu\text{-Cl})]_2$ (0.05 mmol, 31.5 mg) and 4-fluoro-benzaldehyde- N^4 -phenylthiosemicarbazone (L^2) (0.1 mmol, 25.5 mg) were dissolved in 5 mL of dichloromethane and stirred for 3 h. The clear orange solution was evaporated to dryness and afforded a dark red powder, which was subsequently washed with *n*-hexane and dried under reduced pressure. Yield 58.2%. HR-ESI-MS (MeOH) m/z [Found (Calcd)]: 508.2532 (508.6169) $\{[(p\text{-cymene})\text{Ru}(L^2)\text{Cl}] - \text{HCl}\}^+$. ^1H NMR (300 MHz, CDCl_3) δ : 8.903 (1H, s, CH=N), 8.429–8.382 (2H, m, phenyl-*H*), 7.505–7.424 (7H, m, phenyl-*H*), 5.765 (1H, d, $J = 6.0$ Hz, *p*-cym phenyl-*H*), 5.202 (1H, d, $J = 5.9$ Hz, *p*-cym phenyl-*H*), 5.092 (1H, d, $J = 6.0$ Hz, *p*-cym phenyl-*H*), 5.046 (1H, d, $J = 6.0$ Hz, *p*-cym phenyl-*H*), 2.713–2.621 (1H, m, *p*-cym $\text{CH}(\text{CH}_3)_2$), 2.117 (3H, s, *p*-cym CCH_3), 1.224 (3H, d, $J = 6.9$ Hz, *p*-cym $\text{CH}(\text{CH}_3)_2$), 1.165 (3H, d, $J = 6.9$ Hz, *p*-cym $\text{CH}(\text{CH}_3)_2$) ppm. Single crystals suitable for X-ray diffraction were obtained by recrystallization in ethanol and hexane (30/70) solution.

$[(p\text{-cymene})\text{Ru}(L^3)\text{Cl}]\text{Cl}$ ([3]Cl). Compound [3]Cl was synthesized as for [1]Cl. Yield 47.4%. HR-ESI-MS (MeOH) m/z [Found (Calcd)]: 496.2913 (496.6541) $\{[(p\text{-cymene})\text{Ru}(L^3)\text{Cl}] - \text{HCl}\}^+$. ^1H NMR (300 MHz, CDCl_3) δ : 10.747 (1H, s, NHCS), 9.009 (1H, s, NHPH), 8.386 (1H, s, CH=N), 7.823 (1H, d, $J = 4.9$ Hz, thiophene-*H*), 7.598–7.572 (3H, m, thiophene-*H* and phenyl-*H*), 7.459–7.408 (2H, m, phenyl-*H*), 7.346–7.295 (2H, m, thiophene-*H* and phenyl-*H*), 5.580 (1H, d, $J = 5.9$ Hz, *p*-cym phenyl-*H*), 5.272 (1H, d, $J = 5.0$ Hz, *p*-cym phenyl-*H*), 5.177 (1H, d, $J = 5.4$ Hz, *p*-cym phenyl-*H*), 5.139 (1H, d, $J = 6.0$ Hz, *p*-cym phenyl-*H*), 2.771–2.724 (1H, m, *p*-cym $\text{CH}(\text{CH}_3)_2$), 2.178 (3H, s, *p*-cym CCH_3), 1.238 (3H, d, $J = 6.9$ Hz, *p*-cym $\text{CH}(\text{CH}_3)_2$), 1.189 (3H, d, $J = 6.7$ Hz, *p*-cym $\text{CH}(\text{CH}_3)_2$) ppm. Anal. Calcd for $\text{C}_{20}\text{H}_{27}\text{Cl}_2\text{N}_3\text{RuS} \cdot 0.5\text{H}_2\text{O}$: C, 45.97; H, 5.40; N, 8.04; Found: C, 46.24; H, 5.24; N, 8.09. Single crystals suitable for X-ray diffraction were obtained by recrystallization in ethanol and hexane (30/70) solution.

$[(p\text{-cymene})\text{Ru}(L^1)\text{Cl}][(\text{p-cymene})\text{RuCl}_3]$ ([1][*p*-cymene)RuCl₃]). $[(p\text{-cymene})\text{RuCl}(\mu\text{-Cl})]_2$ (0.1 mmol, 63 mg) and benzaldehyde- N^4 -phenylthiosemicarbazone (L^1) (0.1 mmol, 25.5 mg) were dissolved in 5 mL of dichloromethane and stirred for 3 h. The clear orange solution was evaporated to dryness and afforded a dark red powder, which was then washed with *n*-hexane and dried under reduced pressure. Yield 59%. HR-ESI-MS (MeOH, 6 eV, 120 °C) (+) m/z [Found (calcd)]: 490.0909 (490.0897) $\{[(p\text{-cymene})\text{Ru}(L^1)\text{Cl}] - \text{HCl}\}^+$. HR-ESI-MS (MeOH, 6 eV, 120 °C) (–) m/z [Found (calcd)]: 340.8477 (340.9199) $[(p\text{-cymene})\text{RuCl}_3]^-$. ^1H NMR (300 MHz, CDCl_3) δ : 10.394 (1H, s, NHPH), 9.493 (1H, s, CH=N), 8.309–8.284 (2H, m, phenyl-*H*), 7.625–7.551 (5H, m, phenyl-*H*), 7.424–7.373 (2H, m, phenyl-*H*), 7.312 (1H, s, phenyl-*H*), 5.553, 5.336

{4H, $2 \times d$, $^3J_{\text{AB}} = 5.9$ Hz, $[(p\text{-cymene})\text{RuCl}_3]^-$ AA'BB' spin system}, 5.493, 4.937, 4.748, 4.693 {4H, $4 \times d$, $^3J_{\text{AB}} = 5.7$ Hz, $[(p\text{-cymene})\text{Ru}(L^1)\text{Cl}]^+$ AA'BB' spin system}, 3.172, 2.685 (2H, $2 \times m$, $2 \times \text{CH}(\text{CH}_3)_2$), 2.327, 2.071 (6H, $2 \times s$, $2 \times \text{CH}_3$), 1.390, 1.296 (6H, $2 \times d$, $J = 6.9$ Hz, anion- $\text{CH}(\text{CH}_3)_2$), 1.142 (6H, dd, $J = 6.9$ Hz and 12.5 Hz, cation- $\text{CH}(\text{CH}_3)_2$) ppm. Anal. Calcd for $\text{C}_{34}\text{H}_{41}\text{Cl}_4\text{N}_3\text{Ru}_2\text{S} \cdot \text{CH}_3\text{CN}$: C, 47.57; H, 4.88; N, 6.16; Found: C, 47.92; H, 4.57; N, 5.76. Single crystals suitable for X-ray diffraction were obtained by recrystallization in acetonitrile and hexane (30/70) solution.

$[(p\text{-cymene})\text{Ru}(L^2)\text{Cl}][(\text{p-cymene})\text{RuCl}_3]$ ([2][*p*-cymene)RuCl₃]). Compound [2][*p*-cymene)RuCl₃] was synthesized as for [1][*p*-cymene)RuCl₃]. Yield 60.8%. HR-ESI-MS (MeOH, 6 eV, 120 °C) (+) m/z [Found (calcd)]: 508.0794 (508.0802) $\{[(p\text{-cymene})\text{Ru}(L^2)\text{Cl}] - \text{HCl}\}^+$. HR-ESI-MS (MeOH, 6 eV, 120 °C) (–) m/z [Found (calcd)]: 340.9344 (340.9199) $[(\eta^6\text{-p-cymene})\text{RuCl}_3]^-$. ^1H NMR (300 MHz, CDCl_3) δ : 10.358 (1H, s, NHPH), 9.523 (1H, s, CH=N), 8.435–8.389 (2H, m, phenyl-*H*), 7.606 (2H, d, $J = 7.9$ Hz, phenyl-*H*), 7.426–7.375 (2H, m, phenyl-*H*), 7.315–7.291 (2H, m, phenyl-*H*), 7.249 (1H, s, phenyl-*H*), 5.551, 5.343 {4H, $2 \times d$, $^3J_{\text{AB}} = 5.9$ Hz, $[(p\text{-cymene})\text{RuCl}_3]^-$ AA'BB' spin system}, 5.492, 4.999, 4.863, 4.745 {4H, $4 \times d$, $^3J_{\text{AB}} = 5.7$ Hz, $[(p\text{-cymene})\text{Ru}(\text{bzsc})\text{Cl}]^+$ AA'BB' spin system}, 3.163, 2.696 (2H, $2 \times m$, $2 \times \text{CH}(\text{CH}_3)_2$), 2.325, 2.078 (6H, $2 \times s$, $2 \times \text{CH}_3$), 1.388, 1.295 (6H, $2 \times d$, $J = 6.9$ Hz, anion- $\text{CH}(\text{CH}_3)_2$), 1.155 (6H, dd, $J = 6.9$ Hz and 14.0 Hz, cation- $\text{CH}(\text{CH}_3)_2$) ppm. Single crystals suitable for X-ray diffraction were obtained by recrystallization in acetonitrile and hexane (30/70) solution.

$[(p\text{-cymene})\text{Ru}(L^3)\text{Cl}][(\text{p-cymene})\text{RuCl}_3]$ ([3][*p*-cymene)RuCl₃]). Compound [3][*p*-cymene)RuCl₃] was synthesized as for [1][*p*-cymene)RuCl₃]. Yield 66.7%. HR-ESI-MS (MeOH, 6 eV, 120 °C) (+) m/z [Found (calcd)]: 496.0459 (496.0460) $\{[(\eta^6\text{-p-cymene})\text{Ru}(L^3)\text{Cl}] - \text{HCl}\}^+$. HR-ESI-MS (MeOH, 6 eV, 120 °C) (–) m/z [Found (calcd)]: 340.9230 (340.9199) $[(p\text{-cymene})\text{RuCl}_3]^-$. ^1H NMR (300 MHz, CDCl_3) δ : 10.419 (1H, s, NHPH), 9.446 (1H, s, CH=N), 8.357 (1H, d, $J = 3.1$ Hz, thiophene-*H*), 7.774 (1H, d, $J = 4.7$ Hz, thiophene-*H*), 7.606 (2H, d, $J = 7.8$ Hz, phenyl-*H*), 7.420–7.369 (2H, m, thiophene-*H* and phenyl-*H*), 7.306 (1H, s, phenyl-*H*), 7.258–7.232 (1H, m, phenyl-*H*), 5.555, 5.309 {4H, $2 \times d$, $^3J_{\text{AB}} = 5.9$ Hz, $[(p\text{-cymene})\text{RuCl}_3]^-$ AA'BB' spin system}, 5.492, 5.356, 5.142, 5.115 {4H, $4 \times d$, $^3J_{\text{AB}} = 6.0$ Hz, $[(p\text{-cymene})\text{Ru}(\text{bzsc})\text{Cl}]^+$ AA'BB' spin system}, 3.172, 2.791 (2H, $2 \times m$, $2 \times \text{CH}(\text{CH}_3)_2$), 2.324, 2.145 (6H, $2 \times s$, $2 \times \text{CH}_3$), 1.403, 1.293 (6H, $2 \times d$, $J = 6.9$ Hz, anion- $\text{CH}(\text{CH}_3)_2$), 1.198 (6H, dd, $J = 6.8$ Hz and 13.8 Hz, cation- $\text{CH}(\text{CH}_3)_2$) ppm. Anal. Calcd for $\text{C}_{32}\text{H}_{39}\text{Cl}_4\text{N}_3\text{Ru}_2\text{S}_2 \cdot \text{CH}_3\text{CN}$: C, 44.64; H, 4.62; N, 6.12; Found: C, 44.52; H, 4.28; N, 5.96. Single crystals suitable for X-ray diffraction were obtained by recrystallization in acetonitrile and hexane (30/70) solution.

Methods and instrumentantion

NMR spectra were recorded on a Bruker AV-300 spectrometer at working frequencies 300. Chemical shifts were expressed in parts per million (δ) values and coupling constants (J) in Hertz. Mass spectra for the complexes were recorded on a Waters UPLC XEVO G2 TOF mass spectrometer using electrospray ionization probe. Elemental analyses were carried out using an Elementar Vario EL Cube.

X-ray crystallographic determination

All reflection data were collected on a Bruker SMART CCD instrument by using graphite monochromatic Mo $K\alpha$ radiation ($\lambda = 0.71073$ Å) at room temperature. A semiempirical absorption correction by using the SADABS program was applied, and the raw data frame integration was performed with SAINT [18]. The crystal

Download English Version:

<https://daneshyari.com/en/article/1323440>

Download Persian Version:

<https://daneshyari.com/article/1323440>

[Daneshyari.com](https://daneshyari.com)